Launching now in the U.S., INGELVAC CIRCOFLEX® AD is the first vaccine to combine both PCV2a and PCV2d antigens in a single dose designed for optimized herd health. Built on the industry-leading vaccine INGELVAC CIRCOFLEX® from Boehringer Ingelheim, which has set the global standard for PCV2 protection for nearly 20 years, this new dual-antigen approach offers producers an additional option to protect their pigs and support long-term profitability.
PCV2 is one of the most prevalent and economically significant viruses in swine production. Porcine circovirus associated disease (PCVAD) is caused by the PCV2 virus and can lead to severe weight loss, difficulty breathing, and diarrhea. It impairs the immune system, enhancing co-infections and leaving pigs more susceptible to other swine diseases affecting the respiratory, reproductive and digestive systems.
Dr. JD Fiechtner, DVM, is a Senior Key Account Veterinarian at Boehringer Ingelheim Animal Health, where he specializes in swine health. He is known for his expertise on topics like the use of modified-live virus (MLV) vaccines for diseases such as PRRS
